June 2 (Reuters) - VistaGen Therapeutics Inc VTGN.O:
VISTAGEN ON TRACK TO DELIVER TOPLINE DATA FROM FASEDIENOL PALISADE-3 PHASE 3 TRIAL FOR ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER IN THE FOURTH QUARTER OF THIS YEAR
VISTAGEN THERAPEUTICS INC - PALISADE-4 PHASE 3 TRIAL RESULTS EXPECTED IN FIRST HALF OF 2026
Source text: ID:nBwNn1f5a
Further company coverage: VTGN.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.